Anna Shifrina

20130158013, Jun 20, 2013

Jun 1, 2011

13/701471

Anthony C. Blackburn - San Diego CA, US
Anna Shifrina - San Diego CA, US

C07D 223/16
A61K 31/137
A61K 31/55

51421701, 540594

Processes and intermediates for preparing salts of the 5-HT-receptor agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, and pharmaceutically acceptable solvates and hydrates thereof, that are useful for, inter alia, weight management.

20130217706, Aug 22, 2013

Sep 13, 2012

13/614326

Thuy-Anh Tran - San Diego CA, US
Weichao Chen - San Diego CA, US
Bryan A. Kramer - San Diego CA, US
Abu J.M. Sadeque - San Diego CA, US
Anna Shifrina - San Diego CA, US
Pureza Vallar - Chula Vista CA, US
Ning Zou - San Diego CA, US

ARENA PHARMACEUTICALS, INC. - San Diego CA

C07C 271/28
C07C 275/28
C07D 277/48
C07D 333/36
C07C 275/34
C07D 241/20
C07C 275/24
C07D 213/75

51425506, 562439, 514564, 560 27, 514488, 546309, 514352, 549 69, 514447, 514486, 544336, 548196, 514371, 435375

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease; and other diseases.

20130310369, Nov 21, 2013

Aug 31, 2011

13/820126

Anthony C. Blackburn - San Diego CA, US
Jaimie Karyn Rueter - San Diego CA, US
Yun Shan - San Diego CA, US
Anna Shifrina - San Diego CA, US
Scott Stim - San Diego CA, US

A61K 31/55
A61K 31/155

51421701, 540594

Salts of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine with optically active acids, and pharmaceutical compositions comprising them that are useful for, inter alia, weight management.

20130315994, Nov 28, 2013

Aug 31, 2011

13/820107

Zezhi Jesse Shao - San Diego CA, US
Anthony C. Blackburn - San Diego CA, US
Andrew J. Grottick - Chula Vista CA, US
Michael Morgan - San Diego CA, US
Jaimie Karyn Rueter - San Diego CA, US
Anna Shifrina - San Diego CA, US
Scott Stirn - San Diego CA, US
Libo Yang - San Diego CA, US
Woo Hyun Yoon - San Diego CA, US

A61K 9/28
A61K 45/06
A61K 31/55

424468, 540594, 51421701

The present invention relates to methods for weight management that utilize modified-release dosage forms comprising (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts and crystalline forms thereof. The present invention further relates to (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts, crystalline forms thereof and modified-release dosage forms comprising them.

20130317005, Nov 28, 2013

Aug 31, 2011

13/820095

Anthony C. Blackburn - San Diego CA, US
Yun Shan - San Diego CA, US
Anna Shifrina - San Diego CA, US
Scott Stirn - San Diego CA, US

C07D 223/16
A61K 45/06
A61K 31/55

51421109, 540594

Salts of the 5-HT2C-receptor agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, and dosage forms comprising them that are useful for, inter alia, weight management.

20110053958, Mar 3, 2011

Mar 17, 2009

12/933196

Thuy-Anh Tran - San Diego CA, US
Weichao Chen - San Diego CA, US
Bryan A. Kramer - San Diego CA, US
Abu J.M. Sadeque - San Diego CA, US
Anna Shifrina - San Diego CA, US
Young-Jun Shin - San Diego CA, US
Pureza Vallar - Chula Vista CA, US
Ning Zou - San Diego CA, US

ARENA PHARMACEUTICALS, INC. - San Diego CA

A61K 31/4965
C07C 275/18
C07C 275/28
C07C 271/28
C07C 275/34
C07D 213/75
C07D 333/36
C07D 241/20
C07D 277/48
A61K 31/196
A61K 31/27
A61K 31/4406
A61K 31/381
A61K 31/44
A61K 31/426
A61P 7/02
A61P 9/10
A61P 9/00
A61P 11/06
A61P 3/10
A61P 27/02
A61P 27/06
A61P 9/12
A61P 29/00
A61P 17/06
A61P 19/02
A61P 37/06
A61P 25/28
A61P 11/00

51425506, 562439, 560 27, 546309, 549 69, 544336, 546297, 548195, 514564, 514486, 514488, 514353, 514447, 514349, 514371

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

20200375930, Dec 3, 2020

Apr 14, 2020

16/848746

- San Diego CA, US
Weichao CHEN - San Diego CA, US
Bryan A. KRAMER - San Diego CA, US
Abu J.M. SADEQUE - San Diego CA, US
Anna SHIFRINA - San Diego CA, US
Young-Jun SHIN - San Diego CA, US
Pureza VALLAR - Chula Vista CA, US
Ning ZOU - San Diego CA, US

A61K 31/195
C07C 271/12
C07C 275/24
C07C 275/28
C07C 275/30
C07C 275/34
C07C 309/15
C07D 213/75
C07D 241/20
C07D 277/48
C07D 333/36
A61K 31/27
C07C 271/28
A61K 31/325
A61K 31/381
A61K 31/426
A61K 31/44
A61K 31/4402
A61K 31/4406
A61K 31/4965

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: Pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack, angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

20190275055, Sep 12, 2019

Jan 7, 2019

16/241337

- San Diego CA, US
Anthony C. Blackburn - San Diego CA, US
Andrew J. Grottick - Chula Vista CA, US
Michael E. Morgan - San Diego CA, US
Jaimie Karyn Rueter - San Diego CA, US
Anna Shifrina - Alameda CA, US
Scott Stirn - Rancho Santa Fe CA, US
Libo Yang - San Diego CA, US
Woo Hyun Yoon - San Diego CA, US

A61K 31/55
A61K 9/28
A61K 9/20
A61K 9/00
A23P 20/12
A61K 45/06
A61K 31/155
A61K 31/135
C07D 223/16

The present invention relates to methods for weight management that utilize modified-release dosage forms comprising (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts and crystalline forms thereof. The present invention further relates to (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts, crystalline forms thereof and modified-release dosage forms comprising them.